Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2011

View Archived Issues

New tumor-homing peptide improves effects of IL-12 gene therapy in vivo

Long-term phase II data presented on eliglustat in type 1 Gaucher's disease

Final data disclosed from randomized menatetrenone trial in hepatocellular carcinoma

Appetite-regulating hormone gene mutation linked to panic disorder

Korean study identifies new risk factors for vascular dementia and Alzheimer's disease

AtheroNova and Maxwell Biotech sign deal for AHRO-001

Researchers at Incyte prepare new tyrosine-protein kinase JAK inhibitors

Novel IL-1 beta inhibitors presented by Ampla Pharmaceuticals

New PI3K-delta inhibitors disclosed by Roche

Genprex provides update on nanomolecular cancer therapy

BMS synthesizes novel inhibitors of DGL-alpha and DGL-beta

Dynavax Technologies receives NIAID grant

InterMune schedules Esbriet launch in Germany

Oncothyreon starts enrollment in phase II PX-866 trial

Novel IAP inhibitors patented by Aegera Therapeutics

Genentech submits NDA for vismodegib

New injectable sustained-release fluocinolone acetonide to enter clinic for posterior uveitis

ImmunoCellular Therapeutics reports updated data from phase I cancer vaccine trial

Moberg Derma completes recruitment in MOB-015 trial

BioSante Pharmaceuticals completes pharmacokinetic study of LibiGel

Abbott commences ABSORB BTK study

Inovio reports interim data from global HIV vaccine study

Studies evaluate GFT-505 in models of NAFLD/NASH

FDA lifts partial clinical hold on trial of NeuVax in breast cancer

Merck & Co. and BGI join to discover and develop biomarkers and genomic technologies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.